Fiera Capital Corp Supernus Pharmaceuticals, Inc. Transaction History

Fiera Capital Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$25.47 - $33.37 $20.8 Million - $27.3 Million	-817,982 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$29.96 - $38.87 $1.71 Million - $2.22 Million	-57,098 Reduced 6.52%	817,982 $27.1 Million
Q1 2019 May 10, 2019	SELL	$32.77 - $41.99 $2.18 Million - $2.79 Million	-66,450 Reduced 7.06%	875,080 $30.7 Million
Q4 2018 Feb 12, 2019	BUY	$30.84 - $49.51 $1.65 Million - $2.64 Million	53,404 Added 6.01%	941,530 $31.3 Million
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $1.59 Million - $2.11 Million	-37,283 Reduced 4.03%	888,126 $44.7 Million
Q2 2018 Aug 02, 2018	SELL	$44.1 - $59.85 $460,227 - $624,594	-10,436 Reduced 1.12%	925,409 $55.4 Million
Q1 2018 May 11, 2018	SELL	$37.15 - $46.9 $1.86 Million - $2.35 Million	-50,188 Reduced 5.09%	935,845 $42.9 Million
Q4 2017 Feb 09, 2018	SELL	$36.4 - $42.6 $2.13 Million - $2.5 Million	-58,639 Reduced 5.61%	986,033 $39.3 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $38.4 Million - $51.9 Million	1,044,672	1,044,672 $41.8 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Fiera Capital Corp with notifications on news.